News & Events

Seattle, Wash., June 15, 2021 – Umoja Biopharma, an oncology company leveraging its proprietary integrated technologies to reprogram immune cells in vivo to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, today announced the completion of an oversubscribed $210 million Series B financing.

Seattle, WA, June 8, 2021– Umoja Biopharma, a leading oncology company leveraging its proprietary, integrated technologies to reprogram immune cells directly in the human body to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, today announced the appointment of David Fontana, Ph.D., as Chief Business and Strategy Officer.

Umoja Biopharma, a biotechnology company pioneering an integrated, in vivo immunotherapy platform, today announced the appointment of Irena Melnikova, Ph.D., as Chief Financial Officer.

Umoja Biopharma, a biotechnology company pioneering an integrated, in vivo immunotherapy platform, today announced the appointment of Nushmia Khokhar, M.D., as Chief Medical Officer.

Umoja Biopharma, a biotechnology company pioneering an integrated, in vivo immunotherapy platform, today announced the appointment of Rob Glassman, M.D., to its Board of Directors.